WO1996033204A1 - Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) - Google Patents

Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) Download PDF

Info

Publication number
WO1996033204A1
WO1996033204A1 PCT/US1995/005155 US9505155W WO9633204A1 WO 1996033204 A1 WO1996033204 A1 WO 1996033204A1 US 9505155 W US9505155 W US 9505155W WO 9633204 A1 WO9633204 A1 WO 9633204A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
tnf
human
chimeric
cells
Prior art date
Application number
PCT/US1995/005155
Other languages
English (en)
Inventor
Marc Feldmann
Ravinder Nath Maini
James N. Woody
Original Assignee
The Kennedy Institute Of Rheumatology
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kennedy Institute Of Rheumatology, Centocor, Inc. filed Critical The Kennedy Institute Of Rheumatology
Priority to CA002218522A priority Critical patent/CA2218522A1/fr
Priority to JP8531685A priority patent/JPH11503752A/ja
Priority to EP95917696A priority patent/EP0871641A4/fr
Priority to PCT/US1995/005155 priority patent/WO1996033204A1/fr
Priority to AU23657/95A priority patent/AU2365795A/en
Publication of WO1996033204A1 publication Critical patent/WO1996033204A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé pour traiter un individu souffrant d'une maladie liée au facteur nécrosant des tumeurs, consistant à administrer à cet individu des doses multiples d'anticorps anti-TNF, où la seconde dose ou les doses subséquentes sont administrées pendant ou immédiatement avant une rechute due à la maladie. De préférence, la maladie est une maladie liée au facteur TNFα, comme par exemple la polyarthrite rhumatoïde. Cet anticorps anti-TNF peut être un anticorps monoclonal ou l'un de ses fragments, par exemple il peut s'agir d'un anticorps murin, d'un anticorps chimère, d'un anticorps humanisé ou de fragments de ceux-ci. De préférence, l'anticorps se fixe à un ou à plusieurs acides aminés du facteur TNFα humain (hTNFα) choisis dans le groupe 87-108 et 59-80. L'anticorps peut se fixer à l'épitope de A2 ou cA2. Dans la forme d'exécution préférée, l'anticorps est A2 ou cA2.
PCT/US1995/005155 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) WO1996033204A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002218522A CA2218522A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
JP8531685A JPH11503752A (ja) 1995-04-20 1995-04-20 抗ｔｎｆ抗体の複数回投与
EP95917696A EP0871641A4 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
AU23657/95A AU2365795A (en) 1995-04-20 1995-04-20 Multiple administrations of anti-tnf antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002218522A CA2218522A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US44667495A A-371-Of-International 1995-05-30 1995-05-30
US10/252,489 Continuation US20030064070A1 (en) 1995-05-30 2002-09-23 Multiple administrations of anti-TNF antibody

Publications (1)

Publication Number Publication Date
WO1996033204A1 true WO1996033204A1 (fr) 1996-10-24

Family

ID=25679734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/005155 WO1996033204A1 (fr) 1995-04-20 1995-04-20 Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)

Country Status (4)

Country Link
EP (1) EP0871641A4 (fr)
AU (1) AU2365795A (fr)
CA (1) CA2218522A1 (fr)
WO (1) WO1996033204A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005357A1 (fr) * 1996-08-01 1998-02-12 The Kennedy Institute Of Rheumatology Anticorps anti facteur de necrose tumorale et methotrexate dans le traitement des maladies auto-immunes
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US7977464B2 (en) 2000-06-06 2011-07-12 Ucb Pharma S.A. Antibody molecules specific to human tumour necrosis factor alpha
US8889136B2 (en) 2004-04-09 2014-11-18 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8986693B1 (en) 2004-04-09 2015-03-24 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US11091542B2 (en) 2015-12-18 2021-08-17 UCB Biopharma SRL Antibody molecules which bind TNF alpha

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) * 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (fr) * 1989-08-07 1991-02-21 Peptide Technology Ltd Ligands de liaison du facteur de necrose de tumeurs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADERKA ET AL: "THE POSSIBLE ROLE OF TUMOR NECROSIS FACTOR (TNF) AND ITS NATURAL INHIBITORS, THE SOLUBLE-TNF RECEPTORS, IN AUTOIMMUNE DISEASES", ISRAEL JOURNAL OF MEDICAL SCIENCES., ISRAEL MEDICAL ASSOCIATION, TEL AVIV., IL, vol. 28., no. 02., 1 February 1992 (1992-02-01), IL, pages 126 - 130., XP002079556, ISSN: 0021-2180 *
BEUTLER B, ET AL.: "PURIFICATION OF CACHECTIN, A LIPOPROTEIN LIPASE-SUPPRESSING HORMONESECRETED BY ENDOTOXIN BY ENDOTOXIN-INDUCED RAW 264.7 CELLS", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 161, 1 May 1985 (1985-05-01), US, pages 984 - 995, XP002947864, ISSN: 0022-1007, DOI: 10.1084/jem.161.5.984 *
FONG Y, ET AL.: "ANTIBODIES TO CACHECTIN/TUMOR NECROSIS FACTOR REDUCE INTERLEUKIN 1BETA AND INTERLEUKIN 6 APPEARANCE DURING LETHAL BACTEREMIA", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 170, no. 05, 1 November 1989 (1989-11-01), US, pages 1627 - 1633, XP002947866, ISSN: 0022-1007, DOI: 10.1084/jem.170.5.1627 *
GIOVINE DI F S, NUKI G, DUFF G W: "TUMOUR NECROSIS FACTOR IN SYNOVIAL EXUDATES", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 47, 19 February 1988 (1988-02-19), GB, pages 768 - 772, XP001041392, ISSN: 0003-4967 *
MOELLER A, ET AL.: "MONOCLONAL ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR ALPHA: IN VITRO AND IN VIVO APPLICATION", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 02, no. 03, 1 May 1990 (1990-05-01), US, pages 162 - 169, XP002947865, ISSN: 1043-4666, DOI: 10.1016/1043-4666(90)90011-H *
See also references of EP0871641A4 *
TRACEY K J, ET AL.: "ANTI-CACHECTIN/TNF MONOCLONAL ANTIBODIES PREVENT SEPTIC SHOCK DURING LETHAL BACTERAEMIA", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 330, 17 December 1987 (1987-12-17), United Kingdom, pages 662 - 664, XP002947867, ISSN: 0028-0836, DOI: 10.1038/330662a0 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846442B2 (en) 1992-10-08 2010-12-07 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP1941904B1 (fr) * 1996-08-01 2012-05-16 The Mathilda And Terrence Kennedy Institute Of Rheumatology Trust Antagonistes du TNF pour utilisation dans une thérapie adjuvante au méthotrexate dans le traitement des maladies autoimmunes
WO1998005357A1 (fr) * 1996-08-01 1998-02-12 The Kennedy Institute Of Rheumatology Anticorps anti facteur de necrose tumorale et methotrexate dans le traitement des maladies auto-immunes
EP1593393A2 (fr) 1996-08-01 2005-11-09 The Kennedy Institute Of Rheumatology Anticorps contre le TNF et methotrexate pour le traitement de maladies autoimmunes
US8298537B2 (en) 1996-08-01 2012-10-30 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexate
EP1941904A2 (fr) 1996-08-01 2008-07-09 The Kennedy Institute Of Rheumatology Anticorps anti TNF et méthotrexate dans le traitement des maladies auto-immunes
US8383120B2 (en) 1996-08-01 2013-02-26 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate
US7838489B2 (en) 1996-08-01 2010-11-23 The Mathilda And Terence Kennedy Institute Of Rheumatology Trust Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexate
EP1593393B1 (fr) * 1996-08-01 2011-11-30 The Kennedy Institute Of Rheumatology Anticorps contre le TNF et methotrexate pour le traitement concomitant de maladies autoimmunes
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
US6663864B1 (en) 1998-06-10 2003-12-16 Promega Corp. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US7261891B2 (en) 1998-06-10 2007-08-28 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US7977464B2 (en) 2000-06-06 2011-07-12 Ucb Pharma S.A. Antibody molecules specific to human tumour necrosis factor alpha
US9090689B1 (en) 2002-07-19 2015-07-28 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US9512216B2 (en) 2004-04-09 2016-12-06 Abbvie Biotechnology Ltd. Use of TNFα inhibitor
US8961973B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US8986693B1 (en) 2004-04-09 2015-03-24 Abbvie Biotechnology Ltd. Use of TNFα inhibitor for treatment of psoriasis
US9061005B2 (en) 2004-04-09 2015-06-23 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US8889136B2 (en) 2004-04-09 2014-11-18 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US9187559B2 (en) 2004-04-09 2015-11-17 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US9499615B2 (en) 2004-04-09 2016-11-22 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US8961974B2 (en) 2004-04-09 2015-02-24 Abbvie Biotechnology Ltd. Multiple-variable dose regimen for treating TNFα-related disorders
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US11091542B2 (en) 2015-12-18 2021-08-17 UCB Biopharma SRL Antibody molecules which bind TNF alpha

Also Published As

Publication number Publication date
EP0871641A4 (fr) 2001-09-26
EP0871641A1 (fr) 1998-10-21
AU2365795A (en) 1996-11-07
CA2218522A1 (fr) 1996-10-24

Similar Documents

Publication Publication Date Title
US7227003B2 (en) Anti-TNF antibody fragments
US7160543B2 (en) Methods of inhibiting TNF-α in patients with Crohn's disease
US7204985B2 (en) Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
US5656272A (en) Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US20070298040A1 (en) Methods of treating seronegative arthropathy with anti-TNF antibodies
WO1996033204A1 (fr) Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
US20030064070A1 (en) Multiple administrations of anti-TNF antibody
US20020132307A1 (en) Anti-TNF antibodies and peptides of human tumor necrosis factor
JPH11503752A (ja) 抗ｔｎｆ抗体の複数回投与

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 446674

Date of ref document: 19950530

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2218522

Country of ref document: CA

Ref country code: CA

Ref document number: 2218522

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1996 531685

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995917696

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995917696

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995917696

Country of ref document: EP